博时基金王萌：优质资产集聚 港股市场投资机会丰富

Group 1 - The core viewpoint is that the trend of net inflow of southbound funds into Hong Kong stocks is expected to continue in the long term, although the intensity and pace may fluctuate due to market conditions [1] - Professional institutional investors among southbound funds provide liquidity support and are expected to enhance the vitality of sectors such as technology and innovative pharmaceuticals [1] - The listing of high-quality A-share companies in Hong Kong has diversified the types of companies listed, attracting international long-term capital and increasing the willingness of mainland investors to allocate to Hong Kong stocks [1] Group 2 - The technology sector has shown strong performance this year, driven by several factors including the demand for high-end AI servers and GPUs due to AI model training and inference [2] - Internet giants with strong R&D capabilities are competing to develop large models, playing dual roles as "computing power providers" and "model developers" in the AI wave [2] - AI is enabling existing businesses and creating new business models across various applications, such as optimizing advertising on internet platforms and enhancing smart driving capabilities in electric vehicles [2] Group 3 - The innovative pharmaceutical sector in Hong Kong has surged this year, driven by increased demand due to an aging population and rising healthcare expenditures for chronic diseases [3] - Policy changes, such as the reduction of drug approval times and optimization of clinical trial approvals, are accelerating the launch of innovative drugs [3] - The introduction of a new category in the national medical insurance directory is expected to facilitate the entry of high-quality, clinically valuable drugs into hospitals [3]